Core Viewpoint - The Medical Health Index (980016) closed at 6646.6 points, down 0.3%, with a trading volume of 19.922 billion yuan and a turnover rate of 0.75% on October 23 [1] Group 1: Index Performance - Among the constituent stocks of the Medical Health Index, 16 stocks rose while 31 stocks fell, with Kanglong Chemical leading the gainers at 1.55% and Te Bao Biological leading the decliners at 6.07% [1] - The top ten constituent stocks of the Medical Health Index include: - WuXi AppTec (14.37% weight, latest price 101.90, market cap 304.045 billion yuan) - Hengrui Medicine (11.45% weight, latest price 65.14, market cap 432.347 billion yuan) - Mindray Medical (8.07% weight, latest price 221.80, market cap 268.920 billion yuan) [1] Group 2: Capital Flow - The net outflow of main funds from the constituent stocks of the Medical Health Index totaled 1.072 billion yuan, while retail investors saw a net inflow of 955 million yuan [3] - Detailed capital flow for key stocks includes: - Mindray Medical: Main net inflow of 66.9479 million yuan, retail net inflow of 3.6088 million yuan - Te Bao Biological: Main net inflow of 29.0966 million yuan, retail net outflow of 41.3737 million yuan [3]

Group 1 - The core transaction of TEBIO occurred on October 22, with a volume of 232,800 shares and a transaction amount of 17.9978 million yuan, at a price of 77.31 yuan per share [2] - In the last three months, TEBIO has recorded a total of 11 block trades, amounting to 93.7862 million yuan [3] - The closing price of TEBIO on the day of the transaction was 77.31 yuan, reflecting a decrease of 1.58%, with a daily turnover rate of 0.43% and a total trading volume of 136 million yuan [3] Group 2 - The latest margin financing balance for TEBIO is 1.507 billion yuan, with an increase of 19.9255 million yuan over the past five days, representing a growth of 1.34% [4] - TEBIO was established on August 7, 1996, with a registered capital of 406.8 million yuan [4]

Core Insights - The company reported a revenue of 2,479,547,947.46 yuan for the first three quarters of 2025, representing a year-on-year growth of 26.85% [2] - The net profit attributable to shareholders of the listed company was 730,997,712.61 yuan, showing a year-on-year increase of 13.20% [2] Financial Performance - Revenue for the first three quarters of 2025 reached approximately 2.48 billion yuan, indicating strong growth compared to the previous year [2] - The net profit for the same period was around 731 million yuan, reflecting a positive trend in profitability [2]

Core Insights - The company reported a revenue of 2.48 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 26.85% [1] - The net profit attributable to shareholders for the same period was 666 million yuan, showing a year-on-year increase of 20.21% [1] - In the third quarter, the company's revenue reached 969 million yuan, with a year-on-year growth of 26.68% [1] - However, the net profit for the third quarter was 238 million yuan, reflecting a year-on-year decline of 4.63% [1]

Core Insights - The company reported a revenue of 969 million yuan for Q3 2025, representing a year-on-year growth of 26.68% [1] - The net profit for Q3 2025 was 238 million yuan, showing a decline of 4.63% compared to the previous year [1] - For the first three quarters of 2025, the total revenue reached 2.48 billion yuan, with a year-on-year increase of 26.85% [1] - The net profit for the first three quarters was 666 million yuan, reflecting a year-on-year growth of 20.21% [1]

智通财经APP讯，特宝生物(688278.SH)披露2025年第三季度报告，公司前三季度实现营收24.8亿元，同 比增长26.85%;归属于上市公司股东的净利润6.66亿元，同比增长20.21%;扣非净利润6.73亿元，同比增 长15.91%;基本每股收益1.64元。 ...

Core Viewpoint - The company reported a strong revenue growth in Q3 2025, but faced a decline in net profit compared to the previous year [1] Financial Performance - Q3 2025 revenue reached 969 million yuan, representing a year-on-year increase of 26.68% [1] - Q3 2025 net profit was 238 million yuan, showing a year-on-year decrease of 4.63% [1] - For the first three quarters of 2025, total revenue was 2.48 billion yuan, with a year-on-year growth of 26.85% [1] - Net profit for the first three quarters was 666 million yuan, reflecting a year-on-year increase of 20.21% [1] - Basic earnings per share for the first three quarters stood at 1.64 yuan [1]

格隆汇10月22日丨特宝生物(688278.SH)公布，公司前三季度实现营业收入24.8亿元，同比增长 26.85%；归属于上市公司股东的净利润6.66亿元，同比增长20.21%；归属于上市公司股东的扣除非经常 性损益的净利润6.73亿元，同比增长15.91%；基本每股收益1.64元。 ...

Financial Performance - The company's operating revenue for Q3 2025 reached ¥968.93 million, an increase of 26.68% compared to the same period last year[2] - The total profit for the quarter was ¥254.73 million, reflecting a decrease of 9.08% year-over-year[2] - Net profit attributable to shareholders was ¥238.23 million, down 4.63% from the previous year[2] - The basic earnings per share for the quarter was ¥0.59, a decrease of 3.28% compared to the same period last year[2] - Total revenue for the first three quarters of 2025 reached CNY 2,479,547,947.46, a 26.7% increase from CNY 1,954,701,664.76 in the same period of 2024[19] - Net profit for the first three quarters of 2025 was CNY 666,123,781.87, representing a 20.2% increase compared to CNY 554,149,217.81 in 2024[20] - Basic and diluted earnings per share for the first three quarters of 2025 were CNY 1.64, up from CNY 1.36 in the same period of 2024[21] Research and Development - Research and development expenses totaled ¥109.54 million, an increase of 22.90% year-over-year, representing 11.31% of operating revenue[3] - Research and development expenses for the first three quarters of 2025 totaled CNY 279,335,347.75, an increase of 44.5% from CNY 193,341,950.18 in 2024[20] Assets and Liabilities - Total assets at the end of the quarter were ¥3.79 billion, a 24.12% increase from the end of the previous year[3] - Total assets as of the reporting date were CNY 3,786,248,215.19, compared to CNY 3,050,414,835.58 in the previous year[18] - Total liabilities increased to CNY 776,988,289.04 from CNY 497,098,543.83 year-over-year[18] - Non-current assets totaled CNY 1,551,638,564.12, up from CNY 1,223,324,670.50 in the previous year[18] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥471.12 million, an increase of 61.33%[3] - Cash flow from operating activities for the first three quarters of 2025 was CNY 2,454,222,650.87, compared to CNY 1,895,427,035.95 in 2024[23] - Net cash flow from operating activities amounted to ¥471,118,206.70, an increase from ¥292,015,044.33 year-over-year[24] - Cash inflow from investment activities totaled ¥1,047,660,067.17, compared to ¥548,482,799.76 in the previous period[24] - Net cash flow from financing activities was -¥83,917,940.47, a decrease from -¥171,371,528.22 year-over-year[25] Shareholder Information - The company reported a total of 8,608 common shareholders at the end of the reporting period[8] - Major shareholder Yang Ying holds 33.94% of the shares, with a total of 138,077,266 shares[8] Current Assets - As of September 30, 2025, the company's total current assets amounted to RMB 2,234,609,651.07, an increase from RMB 1,827,090,165.08 as of December 31, 2024, reflecting a growth of approximately 22.3%[16] - The company's cash and cash equivalents increased to RMB 449,450,206.30 from RMB 371,821,698.43, representing a growth of about 20.9%[16] - Accounts receivable rose to RMB 788,908,929.03 from RMB 771,496,539.39, indicating a slight increase of approximately 2.3%[16] - Inventory levels increased to RMB 374,644,060.24 from RMB 263,546,426.51, marking a significant rise of around 42.2%[16] Donations and Community Projects - The company has committed to additional donations totaling RMB 8 million for various hepatitis-related projects, with RMB 600,000 already donated during the reporting period[11] - The company has donated RMB 540,000 to the "Oasis Project" aimed at reducing liver cancer incidence among hepatitis patients, with total donations reaching RMB 3,370,000 to date[12] - The company has pledged RMB 900,000 for HBV-related liver cancer prevention projects, with RMB 200,000 donated so far[13] - The company has also committed RMB 1 million to the "Little Bamboo Shoot" children's health project, with RMB 250,000 already contributed[13] Fixed Assets - The company’s fixed assets increased to RMB 608,598,977.21 from RMB 496,526,291.01, reflecting a growth of approximately 22.5%[16] - The company’s construction in progress rose to RMB 267,704,214.37 from RMB 181,556,607.69, indicating an increase of about 47.5%[16]

特宝生物10月22日公告，2025年第三季度实现营业收入9.69亿元，同比增长26.68%；归属于上市公司股 东的净利润2.38亿元，同比下滑4.63%；基本每股收益0.59元。前三季度实现营业收入24.8亿元，同比增 长26.85%；归属于上市公司股东的净利润6.66亿元，同比增长20.21%。 ...